baloxavir marboxil sold brand name xofluza antiviral medication treatment influenza influenza approved medical use japan united states taken single dose may reduce duration flu symptoms day prone selection resistant mutants render baloxavir marboxil developed prodrug strategy metabolism releasing active agent baloxavir acid bxa baloxavir acid functions enzyme inhibitor targeting influenza virus capdependent endonuclease activity used cap snatching virus polymerase complex process essential common side effects baloxavir marboxil include diarrhea bronchitis nausea sinusitis us food drug administration fda considers baloxavir marboxil firstinclass baloxavir marboxil influenza medication individuals twelve years age presented symptoms infection efficacy baloxavir marboxil administered hours october fda approved updated indication treatment acute uncomplicated influenza people twelve years age older risk influenza november fda approved updated indication include postexposure prevention influenza flu people twelve years age older contact individual august fda approved updated indication include postexposure prevention influenza flu people five years age older contact individual eu baloxavir marboxil indicated treatment uncomplicated influenza postexposure prophylaxis influenza individuals aged twelve years age baloxavir marboxil available tablet form granules mixing baloxavir recipients phase ii trial baloxavir recipients phase iii trial infecting influenza strain acquired resistance drug due variants polymerase protein displaying substitutions specifically continuing research clinical concern resistance appearing recipients response treatment baloxavir marboxil coadministered dairy products calciumfortified beverages laxatives antacids oral supplements containing calcium iron magnesium selenium aluminum common side effects following single dose administration baloxavir marboxil include diarrhea bronchitis common cold headache adverse events reported people received baloxavir receiving placebo baloxavir marboxil influenza therapeutic agent specifically enzyme inhibitor targeting influenza virus capdependent endonuclease activity one activities virus polymerase particular inhibits process known cap snatchingmedical citation needed virus derives short capped primers host cell rna transcripts uses polymerasecatalyzed synthesis needed viral polymerase subunit binds host premrnas caps polymerases endonuclease activity catalyzes cleavage nucleotidesmedical citation needed mechanism distinct neuraminidase inhibitors oseltamivir baloxavir marboxil substituted pyridone derivative polycyclic family whose chemical synthesis reported number ways company discovering shionogi co japan well others shionogi reports appeared several times japanese patent literature providing insight possible industrial synthetic routes may baloxavir marboxil bxm prodrug whose active agent baloxavir acid bxa released rapidly vivo hydrolysis baloxavir marboxil catalyzed arylacetamide deacetylases cells blood liver lumen small compound numbers baloxavir marboxil baloxavir acid used publications shionogi others discovery development prior assignment united states adopted name usan respectively reported review patent literature carbonic acid ester carbonate moiety lower lefthand corner image prepared discovery development research late stage precursor treatment chloromethyl methyl september report phase iii randomized controlled trial baloxavir reduced duration influenza symptoms otherwise healthy participants one day compared placebo treatment group comparable seen oseltamivir treatment first day baloxavir started treatment group participants viral loads decreased participants either oseltamivir placebo groups however five days effect viral load single dose baloxavir indistinguishable effect observed following complete regimen oseltamivir treatment needed baloxavir marboxil developed market shionogi co japanese pharmaceutical company switzerlandbased roche names baloxavir marboxil baloxavir acid appear shionogi research reporting respectivelycitation needed japans ministry health labour welfare jmhlw us food drug administration fda approved baloxavir marboxil based evidence benefits side effects two clinical trials adult pediatric participants uncomplicated influenza trial trial involving source neededverification needed trials included clinical sites participants japan trial adding clinical locations united baloxavir marboxil approved sale japan february source needed october fda approved treatment acute uncomplicated influenza people twelve years age older symptomatic fda application baloxavir marboxil granted priority review united states approval xofluza granted shionogi co ltd october specifically fda approved use baloxavir marboxil people high risk developing influenzarelated october fda approved updated indication treatment acute uncomplicated influenza people twelve years age older risk influenza november fda approved updated indication include postexposure prevention influenza flu people twelve years age older contact individual baloxavir marboxil approved medical use australia february safety efficacy baloxavir marboxil antiviral drug taken single oral dose demonstrated two randomized controlled clinical trials subjects participants assigned receive either baloxavir marboxil placebo another antiviral flu treatment within hours experiencing flu trials subjects treated baloxavir marboxil shorter time alleviation symptoms compared subjects took second trial difference time alleviation symptoms subjects received baloxavir marboxil received flu safety efficacy baloxavir marboxil postflu exposure prevention supported one randomized doubleblind controlled trial subjects twelve years age older exposed person influenza household received either single dose baloxavir marboxil single dose subjects received baloxavir marboxil received trials primary endpoint proportion subjects infected influenza virus presented fever least one respiratory symptom day day received baloxavir marboxil subjects met criteria compared subjects received placebo clinical baloxavir marboxil approved medical use european union january httpsenwikipediaorgwikibaloxavirmarboxil